Date:1/11/2012

clinical studies of UGP281 before the end of 2012; the lead molecule for the Type 2 diabetes indication will be selected by the Company with Nordic, early-stage preclinical studies will be conducted and the preclinical results of a lead molecule will be reported in the second half of 2012; at least one feasibility study will convert into a high-value milestone and royalty payment licensing agreement over the next 6-9 months; Cara will report the results from its Phase 1 study in the first quarter of 2012; the Company is well positioned to capitalize on the numerous opportunities that its oral peptide delivery platform and pipeline are expected to realize in 2012; the Company will secure a development partner and licensee for its oral PTH program and, if so, whether it will become a game-changing treatment option for the estimated 75 million people in Europe, the US and Japan who are impacted by osteoporosis; the Company and its stockholders will reap rewards and achieve substantial growth in 2012; and the Company's current cash flow will be sufficient to fund its business operations into the second half of 2012.  We have based these forward-looking statements on our current expectations and projections about future events, including our cash flow projections. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to: the delay in obtaining or the failure to obtain regulatory approvals for our products and the products of our licensees that may generate royalty and milestone payments to us, our ability to achieve product sales and royalties, competition, our dependence on other companies to commercialize, manufacture and sell
'/>"/>

SOURCE Unigene Laboratories, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Unigene Provides 2012 Business Outlook
2. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9
3. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
4. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.
5. Unigene Reports Third Quarter 2011 Financial Results
6. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
7. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
8. Bedford Laboratories™ Issues Guidance on 2011 Voluntary Recall of Polymyxin B for Injection USP and Vecuronium Bromide for Injection Related to Glass Particulates
9. Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories
10. IDEXX Laboratories to Present at J.P. Morgan Healthcare Conference
11. Abaxis Veterinary Reference Laboratories Now Offering Quantitative Lyme Test